Publications by authors named "J Finek"
Article Synopsis
- Combined immuno-oncology regimens, particularly ipilimumab and nivolumab, are widely used for treating metastatic renal cell carcinoma but can lead to notable immune-related adverse effects (irAEs).
- A case study of a 66-year-old man showed rare irAEs, including giant cell temporal arteritis (GCA) and severe encephalopathy, that developed after continued immunotherapy; both conditions were effectively managed with corticosteroids.
- The patient achieved a durable partial response after treatment, emphasizing the need for caution in future immunotherapy decisions, especially for patients with a history of serious irAEs like GCA.
Article Synopsis
- The PLAG1 gene fusions have been found in some uterine myxoid leiomyosarcomas (M-LMS), but there are cases of PLAG1-rearranged uterine sarcomas that do not resemble M-LMS or show smooth muscle markers.
- A study involving 11 cases of these sarcomas showed diverse features, with patient ages ranging from 34 to 72 years and tumor sizes between 6.5 to 32 cm.
- Follow-up data indicated varying outcomes; while some patients showed no disease evidence, others experienced disease progression or died within a few years, and the tumors displayed significant morphological diversity, including unusual characteristics like hyalinized stroma and adipocytic differentiation
Article Synopsis
- The study looked at how well early tumor shrinkage (ETS) could be used in treating cancer patients in the Czech Republic.
- Researchers wanted to know how quickly patients' tumors shrank with new treatments and found that only a few patients had significant shrinkage in the first two months.
- The results suggested that using ETS in everyday cancer treatment is hard and might require extra effort to track patients' progress accurately.
Background: The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic co-morbidities requiring use of various concomitant medications. In the present study, we focused on impact of concomitant antihypertensive medication on the outcomes of mCRPC patients treated with ENZ or ABI.
View Article and Find Full Text PDFBackground/aim: Enzalutamide (ENZ) and abiraterone acetate with prednisone (AAP) represent novel hormonal therapies used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to assess the long-term outcome of mCRPC patients treated with ENZ or AAP in real-life clinical practice.
Patients And Methods: The outcomes of 337 mCRPC patients treated with ENZ or AAP were retrospectively analysed.